4Blondeau JM, Hansen G, Metzler k, et al. J chemother. The role of PK/PD parameters to avoid selection and increase of resistance:mutant prevention concentration. 2004 ; 16 ( Suppl3 ) : 1 -19.
6Clinical and Laboratory Standards Institute.Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement.Clinical and Laboratory Standards Institute,Wayne,Pennsylvania:CLSI,2006,1-150..
7Martin GS,Mannino DM,Eaton S,et al.The epidemiology of sepsis in the United States from 1979 through 2000.N Eng J Med,2003,348:1546-1554.
8Wisplingoff H,Bischoff T,Tallent SM,et al.Nosocomial bloodstream infections in US hospital:analysis of 24,179 cases from a prospective nationwide surveillance study.Clin Infect Dis,2004,39:309-317.
9M100-S16 Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement,2006.
10Hsueh P, Shyr J, Wu J. Decreased erythromycin use after antimicrobial reimbursement restriction for undocumented bacterial upper respiratory tract infections significantly reduced erythromycin resistance in Streptococcus pyogenes in Taiwan. Clin Infect Dis, 2005, 40:903-905.
6Arnold FW, Summersrgill JT, Lajoie AS, et al. A worldwide perspec- tive of atypical pathogens in community acquired pneumonia [J]. Am J Respir Crit Care Med, 2007,175(10) :1086 - 1093.
9Niederman MS,Mandell LA,Anzueto A,et al.Guidelines for the management of adults with community-acquired pueumonia.Diagnosis,assessment of severity,antimicrobial therapy,and prevention[J].Am J Respir Crit Care Med,2001,163(7):1 730.
10Burkhardt O,Welte T.10 years’experience with the pneumococcal quinolone moxifloxacin[J].Expert Rev Anti Infect Ther,2009,7(6):645.
